Skip to main content

Develco receives 10 million euros as growth capital

| News

Develco receives 10 million euros as growth capital

10.10.2024

Basel Area-based Develco Pharma is receiving 10 million euros to expand its production capacities, product developments, and technologies. The investors are SHS Capital and other shareholders.

Research and development is a high priority at Develco (image taken from a Develco Pharma brochure)

Develco Pharma Schweiz AG with headquarters in Pratteln in the Swiss canton of Basel-Landschaft is receiving an additional 10 million euros from its investors to promote production and product developments. Develco specializes in innovative drug formulations with an extended-release effect for pain management and other therapeutic areas. After authorization, the products will be outlicensed to international pharmaceutical companies.

According to a press releaseSHS Capital in Tübingen, Germany, plus some of its limited partners and other shareholders are investing additional capital in Develco Pharma. SHS Capital has been investing in Develco since 2020. The initial aim was to build up efficient management. According to a corporate statement from Develco, it has expanded its product portfolio since 2020 by introducing new medicines and registering existing products in additional countries.

Investment helps to scale operations

CEO of Develco Martin Renner commented: “We welcome the new investment to help us scale our operations, increase the investments in our product development, and further expand our technological capabilities. This will allow us to meet the growing market demand and remain at the forefront of our field.”

Manfred Ulmer-Weber, Managing Partner at SHS and Member of the Board at Develco, stated: “Develco has demonstrated excellence in a highly specialized industry, and with this additional capital, we are confident we can elevate Develco to new heights and further accelerate its growth trajectory.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.